{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:59:42Z","timestamp":1795089582829,"version":"4.10.2"},"reference-count":250,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41571-019-0297-y","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T06:02:49Z","timestamp":1576562569000},"page":"147-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1437,"title":["Engineering strategies to overcome the current roadblocks in CAR T cell therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Sarwish","family":"Rafiq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4692-2433","authenticated-orcid":false,"given":"Christopher S.","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"297_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson, H. J., Rafiq, S. & Brentjens, R. J. Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13, 370\u2013383 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"297_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"297_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"297_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"297_CR5","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545\u20132554 (2017).","journal-title":"N. Engl. J. Med."},{"key":"297_CR6","unstructured":"U.S. Food & Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. fda.gov https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome (2017)."},{"key":"297_CR7","unstructured":"U.S. Food & Drug Administration. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. fda.gov https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma (2017)."},{"key":"297_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.phrs.2017.11.035","volume":"129","author":"MC Ramello","year":"2018","unstructured":"Ramello, M. C., Haura, E. B. & Abate-Daga, D. CAR-T cells and combination therapies: what's next in the immunotherapy revolution? Pharmacol. Res. 129, 194\u2013203 (2018).","journal-title":"Pharmacol. Res."},{"issue":"12","key":"297_CR9","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41587-019-0137-8","volume":"37","author":"Stefanie R. Bailey","year":"2019","unstructured":"Bailey, S. R. & Maus, M. V. Gene editing for immune cell therapies. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-019-0137-8 (2019).","journal-title":"Nature Biotechnology"},{"key":"297_CR10","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3389\/fimmu.2018.03180","volume":"9","author":"A Dwivedi","year":"2019","unstructured":"Dwivedi, A., Karulkar, A., Ghosh, S., Rafiq, A. & Purwar, R. Lymphocytes in cellular therapy: functional regulation of CAR T cells. Front. Immunol. 9, 3180 (2019).","journal-title":"Front. Immunol."},{"key":"297_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep03571","volume":"4","author":"G Zhang","year":"2014","unstructured":"Zhang, G. et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci. Rep. 4, 3571 (2014).","journal-title":"Sci. Rep."},{"key":"297_CR12","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.4049\/jimmunol.1301769","volume":"193","author":"R Oren","year":"2014","unstructured":"Oren, R. et al. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity\/avidity thresholds. J. Immunol. 193, 5733\u20135743 (2014).","journal-title":"J. Immunol."},{"key":"297_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/gt.2014.30","volume":"21","author":"Y Inaguma","year":"2014","unstructured":"Inaguma, Y. et al. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H. Gene Ther. 21, 575\u2013584 (2014).","journal-title":"Gene Ther."},{"key":"297_CR14","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/leu.2016.373","volume":"31","author":"S Rafiq","year":"2017","unstructured":"Rafiq, S. et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen. Leukemia 31, 1788\u20131797 (2017).","journal-title":"Leukemia"},{"key":"297_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nchembio.2565","volume":"14","author":"ZL Chang","year":"2018","unstructured":"Chang, Z. L. et al. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat. Chem. Biol. 14, 317\u2013324 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"297_CR16","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1073\/pnas.1817147116","volume":"116","author":"YJ Xie","year":"2019","unstructured":"Xie, Y. J. et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc. Natl Acad. Sci. USA 116, 7624\u20137631 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"297_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","volume":"11","author":"EL Smith","year":"2019","unstructured":"Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11, eaau7746 (2019).","journal-title":"Sci. Transl. Med."},{"key":"297_CR18","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.ymthe.2018.03.016","volume":"26","author":"EL Smith","year":"2018","unstructured":"Smith, E. L. et al. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol. Ther. 26, 1447\u20131456 (2018).","journal-title":"Mol. Ther."},{"key":"297_CR19","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1111\/j.1742-4658.2011.08207.x","volume":"278","author":"A Chailyan","year":"2011","unstructured":"Chailyan, A., Marcatili, P. & Tramontano, A. The association of heavy and light chain variable domains in antibodies: implications for antigen specificity. FEBS J. 278, 2858\u20132866 (2011).","journal-title":"FEBS J."},{"key":"297_CR20","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","volume":"19","author":"M Hudecek","year":"2013","unstructured":"Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153\u20133164 (2013).","journal-title":"Clin. Cancer Res."},{"key":"297_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/leu.2016.35","volume":"30","author":"RC Lynn","year":"2016","unstructured":"Lynn, R. C. et al. High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia 30, 1355\u20131364 (2016).","journal-title":"Leukemia"},{"key":"297_CR22","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 75, 3596\u20133607 (2015).","journal-title":"Cancer Res."},{"key":"297_CR23","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso, H. G. et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 75, 3505\u20133518 (2015).","journal-title":"Cancer Res."},{"key":"297_CR24","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1182\/blood.V124.21.4799.4799","volume":"124","author":"K Watanabe","year":"2014","unstructured":"Watanabe, K. et al. Excessively high-affinity single-chain fragment variable region in a chimeric antigen receptor can counteract T-cell proliferation. Blood 124, 4799\u20134799 (2014).","journal-title":"Blood"},{"key":"297_CR25","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408\u20131414 (2019).","journal-title":"Nat. Med."},{"key":"297_CR26","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina, A. & Maher, J. Strategies to address chimeric antigen receptor tonic signaling. Mol. Cancer Ther. 17, 1795\u20131815 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"297_CR27","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"297_CR28","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","volume":"131","author":"L Lee","year":"2018","unstructured":"Lee, L. et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood 131, 746\u2013758 (2018).","journal-title":"Blood"},{"key":"297_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. J. Hematol. Oncol. 11, 60 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"297_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-016-0256-3","volume":"9","author":"Y Nakazawa","year":"2016","unstructured":"Nakazawa, Y. et al. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34+ cells of juvenile myelomonocytic leukemia. J. Hematol. Oncol. 9, 27 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"297_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister, S. H. et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol. Res. 7, 100\u2013112 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40425-015-0099-4","volume":"3","author":"JA Hammill","year":"2015","unstructured":"Hammill, J. A. et al. Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. J. Immunother. Cancer 3, 55 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"297_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1089\/hum.2017.021","volume":"28","author":"E Siegler","year":"2017","unstructured":"Siegler, E., Li, S., Kim, Y. J. & Wang, P. Designed ankyrin repeat proteins as Her2 targeting domains in chimeric antigen receptor-engineered T cells. Hum. Gene Ther. 28, 726\u2013736 (2017).","journal-title":"Hum. Gene Ther."},{"key":"297_CR34","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1016\/j.ymthe.2017.07.009","volume":"25","author":"X Han","year":"2017","unstructured":"Han, X. et al. Adnectin-based design of chimeric antigen receptor for T cell engineering. Mol. Ther. 25, 2466\u20132476 (2017).","journal-title":"Mol. Ther."},{"key":"297_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","volume":"33","author":"MC Jensen","year":"2015","unstructured":"Jensen, M. C. & Riddell, S. R. Designing chimeric antigen receptors to effectively and safely target tumors. Curr. Opin. Immunol. 33, 9\u201315 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"297_CR36","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza, L. et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol. Ther. 25, 2452\u20132465 (2017).","journal-title":"Mol. Ther."},{"key":"297_CR37","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","volume":"180","author":"SE James","year":"2008","unstructured":"James, S. E. et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J. Immunol. 180, 7028\u20137038 (2008).","journal-title":"J. Immunol."},{"key":"297_CR38","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2012-06-438002","volume":"121","author":"W Haso","year":"2013","unstructured":"Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165\u20131174 (2013).","journal-title":"Blood"},{"key":"297_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-017-0088-z","volume":"6","author":"L Qin","year":"2017","unstructured":"Qin, L., Zhao, R. & Li, P. Incorporation of functional elements enhances the antitumor capacity of CAR T cells. Exp. Hematol. Oncol. 6, 28 (2017).","journal-title":"Exp. Hematol. Oncol."},{"key":"297_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1253656","volume":"5","author":"N Watanabe","year":"2016","unstructured":"Watanabe, N. et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology 5, e1253656 (2016).","journal-title":"Oncoimmunology"},{"key":"297_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","volume":"28","author":"RD Guest","year":"2005","unstructured":"Guest, R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J. Immunother. 28, 203\u2013211 (2005).","journal-title":"J. Immunother."},{"key":"297_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125\u2013135 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR43","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/gt.2010.91","volume":"17","author":"A Hombach","year":"2010","unstructured":"Hombach, A., Hombach, A. A. & Abken, H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther. 17, 1206\u20131213 (2010).","journal-title":"Gene Ther."},{"key":"297_CR44","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/mt.2014.208","volume":"23","author":"M Jonnalagadda","year":"2015","unstructured":"Jonnalagadda, M. et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol. Ther. 23, 757\u2013768 (2015).","journal-title":"Mol. Ther."},{"key":"297_CR45","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.4049\/jimmunol.0901766","volume":"184","author":"JS Bridgeman","year":"2010","unstructured":"Bridgeman, J. S. et al. The optimal antigen response of chimeric antigen receptors harboring the CD3\u03b6 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR\/CD3 complex. J. Immunol. 184, 6938\u20136949 (2010).","journal-title":"J. Immunol."},{"key":"297_CR46","doi-asserted-by":"publisher","first-page":"96976","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3, 96976 (2018).","journal-title":"JCI Insight"},{"key":"297_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti, G., Gottschalk, S., Savoldo, B. & Brenner, M. K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257, 107\u2013126 (2014).","journal-title":"Immunol. Rev."},{"key":"297_CR48","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","volume":"181","author":"T Brocker","year":"1995","unstructured":"Brocker, T. & Karjalainen, K. Signals through T cell receptor-\u03b6 chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 181, 1653\u20131659 (1995).","journal-title":"J. Exp. Med."},{"key":"297_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor. Nat. Biotechnol. 20, 70\u201375 (2002).","journal-title":"Nat. Biotechnol."},{"key":"297_CR50","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Riviere, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"297_CR51","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 712 (2016).","journal-title":"Immunity"},{"key":"297_CR52","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","volume":"7","author":"M Mata","year":"2017","unstructured":"Mata, M. et al. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov. 7, 1306\u20131319 (2017).","journal-title":"Cancer Discov."},{"key":"297_CR53","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/onci.19855","volume":"1","author":"AA Hombach","year":"2012","unstructured":"Hombach, A. A., Heiders, J., Foppe, M., Chmielewski, M. & Abken, H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. Oncoimmunology 1, 458\u2013466 (2012).","journal-title":"Oncoimmunology"},{"key":"297_CR54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/hum.2012.247","volume":"24","author":"AA Hombach","year":"2013","unstructured":"Hombach, A. A., Chmielewski, M., Rappl, G. & Abken, H. Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum. Gene Ther. 24, 259\u2013269 (2013).","journal-title":"Hum. Gene Ther."},{"key":"297_CR55","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","volume":"124","author":"S Guedan","year":"2014","unstructured":"Guedan, S. et al. ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells. Blood 124, 1070\u20131080 (2014).","journal-title":"Blood"},{"key":"297_CR56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4161\/onci.19458","volume":"1","author":"DG Song","year":"2012","unstructured":"Song, D. G. & Powell, D. J. Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy. Oncoimmunology 1, 547\u2013549 (2012).","journal-title":"Oncoimmunology"},{"key":"297_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063037","volume":"8","author":"CP Duong","year":"2013","unstructured":"Duong, C. P. et al. Engineering T cell function using chimeric antigen receptors identified using a DNA library approach. PLOS ONE 8, e63037 (2013).","journal-title":"PLOS ONE"},{"key":"297_CR58","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1158\/2326-6066.CIR-15-0054","volume":"3","author":"E Wang","year":"2015","unstructured":"Wang, E. et al. Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors. Cancer Immunol. Res. 3, 815\u2013826 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 34, 45\u201355 (2019).","journal-title":"Blood Rev."},{"key":"297_CR60","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"297_CR61","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958\u2013971 (2018).","journal-title":"Cancer Discov."},{"key":"297_CR62","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295\u20132306 (2017).","journal-title":"Blood"},{"key":"297_CR63","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).","journal-title":"Sci. Transl. Med."},{"key":"297_CR64","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","volume":"8","author":"MC Milone","year":"2018","unstructured":"Milone, M. C. & Bhoj, V. G. The pharmacology of T cell therapies. Mol. Ther. Methods Clin. Dev. 8, 210\u2013221 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"297_CR65","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ van der Stegen","year":"2015","unstructured":"van der Stegen, S. J., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 14, 499\u2013509 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"297_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).","journal-title":"Sci. Signal."},{"key":"297_CR67","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying, Z. et al. A safe and potent anti-CD19 CAR T cell therapy. Nat. Med. 25, 947\u2013953 (2019).","journal-title":"Nat. Med."},{"key":"297_CR68","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/leu.2017.57","volume":"31","author":"D Sommermeyer","year":"2017","unstructured":"Sommermeyer, D. et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia 31, 2191-2199 (2017).","journal-title":"Leukemia"},{"key":"297_CR69","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner, R. M. et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 133, 697\u2013709 (2019).","journal-title":"Blood"},{"key":"297_CR70","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","volume":"294","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva, M., Duchateau, P., Depil, S., Poirot, L. & Valton, J. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J. Biol. Chem. 294, 5430\u20135437 (2019).","journal-title":"J. Biol. Chem."},{"key":"297_CR71","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"297_CR72","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"297_CR73","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke, V. et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564, 273\u2013277 (2018).","journal-title":"Nature"},{"key":"297_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10565-7","volume":"10","author":"YG Lee","year":"2019","unstructured":"Lee, Y. G. et al. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. Nat. Commun. 10, 2681 (2019).","journal-title":"Nat. Commun."},{"key":"297_CR75","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers, D. T. et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc. Natl Acad. Sci. USA 113, E459\u2013E468 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"297_CR76","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1089\/10430340460732463","volume":"15","author":"M Serafini","year":"2004","unstructured":"Serafini, M. et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum. Gene Ther. 15, 63\u201376 (2004).","journal-title":"Hum. Gene Ther."},{"key":"297_CR77","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","volume":"94","author":"M Griffioen","year":"2009","unstructured":"Griffioen, M. et al. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 94, 1316\u20131320 (2009).","journal-title":"Haematologica"},{"key":"297_CR78","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","volume":"124","author":"B Philip","year":"2014","unstructured":"Philip, B. et al. A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy. Blood 124, 1277\u20131287 (2014).","journal-title":"Blood"},{"key":"297_CR79","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255\u20131263 (2011).","journal-title":"Blood"},{"key":"297_CR80","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011).","journal-title":"N. Engl. J. Med."},{"key":"297_CR81","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-019-0537-3","volume":"19","author":"A Juillerat","year":"2019","unstructured":"Juillerat, A. et al. Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnol. 19, 44 (2019).","journal-title":"BMC Biotechnol."},{"key":"297_CR82","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci. Transl. Med. 11, eaau5907 (2019).","journal-title":"Sci. Transl. Med."},{"key":"297_CR83","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med."},{"key":"297_CR84","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CHJ Lamers","year":"2013","unstructured":"Lamers, C. H. J. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904\u2013912 (2013).","journal-title":"Mol. Ther."},{"key":"297_CR85","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"297_CR86","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman, A. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20, 1215\u20131221 (2002).","journal-title":"J. Clin. Oncol."},{"key":"297_CR87","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed, N. et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688\u20131696 (2015).","journal-title":"J. Clin. Oncol."},{"key":"297_CR88","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff, S. L. et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J. Immunother. 42, 126\u2013135 (2019).","journal-title":"J. Immunother."},{"key":"297_CR89","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","volume":"66","author":"FC Thistlethwaite","year":"2017","unstructured":"Thistlethwaite, F. C. et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol. Immunother. 66, 1425\u20131436 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"297_CR90","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1271857","volume":"8","author":"HG Caruso","year":"2018","unstructured":"Caruso, H. G., Heimberger, A. B. & Cooper, L. J. N. Steering CAR T cells to distinguish friend from foe. Oncoimmunology 8, e1271857 (2018).","journal-title":"Oncoimmunology"},{"key":"297_CR91","doi-asserted-by":"publisher","first-page":"23735","DOI":"10.18632\/oncotarget.4362","volume":"6","author":"K Liu","year":"2015","unstructured":"Liu, K. et al. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging. Oncotarget 6, 23735\u201323747 (2015).","journal-title":"Oncotarget"},{"key":"297_CR92","doi-asserted-by":"publisher","first-page":"21533","DOI":"10.18632\/oncotarget.4071","volume":"6","author":"D-G Song","year":"2015","unstructured":"Song, D.-G. et al. A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget 6, 21533\u201321546 (2015).","journal-title":"Oncotarget"},{"key":"297_CR93","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman, S. A. et al. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol. Res. 6, 36\u201346 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR94","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KoleT Roybal","year":"2016","unstructured":"Roybal, KoleT. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770\u2013779 (2016).","journal-title":"Cell"},{"key":"297_CR95","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489\u2013503.e8 (2019).","journal-title":"Cancer Cell"},{"key":"297_CR96","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71\u201375 (2013).","journal-title":"Nat. Biotechnol."},{"key":"297_CR97","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","volume":"32","author":"S Wilkie","year":"2012","unstructured":"Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32, 1059\u20131070 (2012).","journal-title":"J. Clin. Immunol."},{"key":"297_CR98","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","volume":"1","author":"E Lanitis","year":"2013","unstructured":"Lanitis, E. et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res. 1, 43\u201353 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR99","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen, A. M. et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22, 1211\u20131220 (2014).","journal-title":"Mol. Ther."},{"key":"297_CR100","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013).","journal-title":"Sci. Transl. Med."},{"key":"297_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/srep39833","volume":"7","author":"A Juillerat","year":"2017","unstructured":"Juillerat, A. et al. An oxygen sensitive self-decision making engineered CAR T-cell. Sci. Rep. 7, 39833 (2017).","journal-title":"Sci. Rep."},{"key":"297_CR102","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou, J. et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer. Cancer Immunol. Res. 5, 1152\u20131161 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR103","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","volume":"350","author":"CY Wu","year":"2015","unstructured":"Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J. & Lim, W. A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077 (2015).","journal-title":"Science"},{"key":"297_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/srep18950","volume":"6","author":"A Juillerat","year":"2016","unstructured":"Juillerat, A. et al. Design of chimeric antigen receptors with integrated controllable transient functions. Sci. Rep. 6, 18950 (2016).","journal-title":"Sci. Rep."},{"key":"297_CR105","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3389\/fimmu.2018.01409","volume":"9","author":"J Fisher","year":"2018","unstructured":"Fisher, J. & Anderson, J. Engineering approaches in human gamma delta T cells for cancer immunotherapy. Front. Immunol. 9, 1409 (2018).","journal-title":"Front. Immunol."},{"key":"297_CR106","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.ymthe.2017.03.002","volume":"25","author":"J Fisher","year":"2017","unstructured":"Fisher, J. et al. Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor. Mol. Ther. 25, 1234\u20131247 (2017).","journal-title":"Mol. Ther."},{"key":"297_CR107","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim, M. Y. et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 173, 1439\u20131453.e19 (2018).","journal-title":"Cell"},{"key":"297_CR108","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"297_CR109","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41591-018-0212-6","volume":"24","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S. & Brentjens, R. J. Tumors evading CARs \u2014 the chase is on. Nat. Med. 24, 1492\u20131493 (2018).","journal-title":"Nat. Med."},{"key":"297_CR110","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","volume":"33","author":"J Pan","year":"2019","unstructured":"Pan, J. et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 33, 2854\u20132866 (2019).","journal-title":"Leukemia"},{"key":"297_CR111","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1200\/JCO.2019.37.15_suppl.2510","volume":"37","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. et al. Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma. J. Clin. Oncol. 37, 2510\u20132510 (2019).","journal-title":"J. Clin. Oncol."},{"key":"297_CR112","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","volume":"16","author":"KM Mahadeo","year":"2019","unstructured":"Mahadeo, K. M. et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol. 16, 45\u201363 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"297_CR113","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847 (2017).","journal-title":"N. Engl. J. Med."},{"key":"297_CR114","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049\u20131058 (2019).","journal-title":"Nat. Biotechnol."},{"key":"297_CR115","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/mt.2015.4","volume":"23","author":"KJ Curran","year":"2015","unstructured":"Curran, K. J. et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol. Ther. 23, 769\u2013778 (2015).","journal-title":"Mol. Ther."},{"key":"297_CR116","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473\u2013488.e6 (2019).","journal-title":"Cancer Cell"},{"key":"297_CR117","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","volume":"167","author":"M Boice","year":"2016","unstructured":"Boice, M. et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell 167, 405\u2013418.e13 (2016).","journal-title":"Cell"},{"key":"297_CR118","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.smim.2016.02.001","volume":"28","author":"DH Busch","year":"2016","unstructured":"Busch, D. H., Fr\u00e4\u00dfle, S. P., Sommermeyer, D., Buchholz, V. R. & Riddell, S. R. Role of memory T cell subsets for adoptive immunotherapy. Semin. Immunol. 28, 28\u201334 (2016).","journal-title":"Semin. Immunol."},{"key":"297_CR119","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3389\/fimmu.2018.02493","volume":"9","author":"MA Morgan","year":"2018","unstructured":"Morgan, M. A. & Schambach, A. Engineering CAR-T cells for improved function against solid tumors. Front. Immunol. 9, 2493 (2018).","journal-title":"Front. Immunol."},{"key":"297_CR120","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/bloodadvances.2017011254","volume":"2","author":"CT Petersen","year":"2018","unstructured":"Petersen, C. T. et al. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3K\u03b4 inhibitors and VIP antagonists. Blood Adv. 2, 210\u2013223 (2018).","journal-title":"Blood Adv."},{"key":"297_CR121","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"297_CR122","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci. Transl. Med. 8, 355ra116 (2016).","journal-title":"Sci. Transl. Med."},{"key":"297_CR123","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","volume":"128","author":"M Sabatino","year":"2016","unstructured":"Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128, 519\u2013528 (2016).","journal-title":"Blood"},{"key":"297_CR124","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P. & Rosenberg, S. A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875\u20133886 (2010).","journal-title":"Blood"},{"key":"297_CR125","doi-asserted-by":"crossref","first-page":"57.28","DOI":"10.4049\/jimmunol.200.Supp.57.28","volume":"200","author":"JC Boucher","year":"2018","unstructured":"Boucher, J. C. et al. Mutation of the CD28 costimulatory domain confers increased CAR T cell persistence and decreased exhaustion. J. Immunol. 200, 57.28 (2018).","journal-title":"J. Immunol."},{"key":"297_CR126","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"297_CR127","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"297_CR128","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood-2018-99-117737","volume":"132","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. A phase I first-in-human clinical trial of CD19-targeted 19-28z\/4-1BBL \"armored\" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation. Blood 132, 224 (2018).","journal-title":"Blood"},{"key":"297_CR129","unstructured":"Centers for Disease Control and Prevention. United States Cancer Statistics: Data Visualizations https:\/\/www.cdc.gov\/cancer\/dataviz (2019)."},{"key":"297_CR130","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346\u2013354 (2013).","journal-title":"Nature"},{"key":"297_CR131","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","volume":"6","author":"A Wing","year":"2018","unstructured":"Wing, A. et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol. Res. 6, 605\u2013616 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR132","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","volume":"72","author":"K Urbanska","year":"2012","unstructured":"Urbanska, K. et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72, 1844\u20131852 (2012).","journal-title":"Cancer Res."},{"key":"297_CR133","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1368604","volume":"7","author":"JJ Lohmueller","year":"2017","unstructured":"Lohmueller, J. J., Ham, J. D., Kvorjak, M. & Finn, O. J. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology 7, e1368604 (2017).","journal-title":"Oncoimmunology"},{"key":"297_CR134","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","volume":"18","author":"K Tamada","year":"2012","unstructured":"Tamada, K. et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin. Cancer Res. 18, 6436\u20136445 (2012).","journal-title":"Clin. Cancer Res."},{"key":"297_CR135","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1021\/jacs.5b00106","volume":"137","author":"MS Kim","year":"2015","unstructured":"Kim, M. S. et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J. Am. Chem. Soc. 137, 2832\u20132835 (2015).","journal-title":"J. Am. Chem. Soc."},{"key":"297_CR136","first-page":"E450","volume":"113","author":"JSY Ma","year":"2016","unstructured":"Ma, J. S. Y. et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc. Natl Acad. Sci. USA 113, E450\u2013E458 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"297_CR137","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1158\/0008-5472.CAN-18-1834","volume":"79","author":"YG Lee","year":"2019","unstructured":"Lee, Y. G. et al. Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. Cancer Res. 79, 387\u2013396 (2019).","journal-title":"Cancer Res."},{"key":"297_CR138","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/0008-5472.CAN-13-1365","volume":"74","author":"K Kudo","year":"2014","unstructured":"Kudo, K. et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 74, 93\u2013103 (2014).","journal-title":"Cancer Res."},{"key":"297_CR139","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426\u20131438.e11 (2018).","journal-title":"Cell"},{"key":"297_CR140","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112\u2013120 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR141","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","volume":"21","author":"SC Katz","year":"2015","unstructured":"Katz, S. C. et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin. Cancer Res. 21, 3149\u20133159 (2015).","journal-title":"Clin. Cancer Res."},{"key":"297_CR142","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jvir.2018.03.001","volume":"29","author":"JC Hardaway","year":"2018","unstructured":"Hardaway, J. C., Prince, E., Arepally, A. & Katz, S. C. Regional infusion of chimeric antigen receptor T cells to overcome barriers for solid tumor immunotherapy. J. Vasc. Interv. Radiol. 29, 1017\u20131021.e1 (2018).","journal-title":"J. Vasc. Interv. Radiol."},{"key":"297_CR143","doi-asserted-by":"publisher","first-page":"E92","DOI":"10.3390\/cancers9070092","volume":"9","author":"P Sridhar","year":"2017","unstructured":"Sridhar, P. & Petrocca, F. Regional delivery of chimeric antigen receptor (CAR) T-cells for cancer therapy. Cancers 9, E92 (2017).","journal-title":"Cancers"},{"key":"297_CR144","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth, N., Wicha, M. S. & Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559\u2013572 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"297_CR145","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.molimm.2007.09.010","volume":"45","author":"AS Lo","year":"2008","unstructured":"Lo, A. S. et al. Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. Mol. Immunol. 45, 1276\u20131287 (2008).","journal-title":"Mol. Immunol."},{"key":"297_CR146","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","volume":"113","author":"A Di Stasi","year":"2009","unstructured":"Di Stasi, A. et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392\u20136402 (2009).","journal-title":"Blood"},{"key":"297_CR147","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock, J. A. et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33, 780\u2013788 (2010).","journal-title":"J. Immunother."},{"key":"297_CR148","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon, E. K. et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719\u20134730 (2011).","journal-title":"Clin. Cancer Res."},{"key":"297_CR149","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran, E. et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210, 1125\u20131135 (2013).","journal-title":"J. Exp. Med."},{"key":"297_CR150","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang, L. C. et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2, 154\u2013166 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR151","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana, I. et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21, 524\u2013529 (2015).","journal-title":"Nat. Med."},{"key":"297_CR152","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12307-018-0208-2","volume":"11","author":"A Mardomi","year":"2018","unstructured":"Mardomi, A. & Abediankenari, S. Matrix metalloproteinase 8: could it benefit the CAR-T cell therapy of solid tumors? - a- Commentary on therapeutic potential. Cancer Microenviron. 11, 93\u201396 (2018).","journal-title":"Cancer Microenviron."},{"key":"297_CR153","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1200\/JCO.18.01295","volume":"37","author":"RK Ramanathan","year":"2019","unstructured":"Ramanathan, R. K. et al. Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J. Clin. Oncol. 37, 1062\u20131069 (2019).","journal-title":"J. Clin. Oncol."},{"key":"297_CR154","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","volume":"36","author":"SR Hingorani","year":"2018","unstructured":"Hingorani, S. R. et al. HALO 202: Randomized phase II study of PEGPH20 plus Nab-paclitaxel\/gemcitabine versus Nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol. 36, 359\u2013366 (2018).","journal-title":"J. Clin. Oncol."},{"key":"297_CR155","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33, 1974\u20131982 (2015).","journal-title":"J. Clin. Oncol."},{"key":"297_CR156","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","volume":"20","author":"EK Moon","year":"2014","unstructured":"Moon, E. K. et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin. Cancer Res. 20, 4262\u20134273 (2014).","journal-title":"Clin. Cancer Res."},{"key":"297_CR157","doi-asserted-by":"publisher","first-page":"E340","DOI":"10.3390\/ijms19020340","volume":"19","author":"DH Yoon","year":"2018","unstructured":"Yoon, D. H., Osborn, M. J., Tolar, J. & Kim, C. J. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T. Int. J. Mol. Sci. 19, E340 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"297_CR158","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","volume":"132","author":"AM Li","year":"2018","unstructured":"Li, A. M. et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. Blood 132, 556 (2018).","journal-title":"Blood"},{"key":"297_CR159","first-page":"4121","volume":"130","author":"EA Chong","year":"2017","unstructured":"Chong, E. A. et al. Phase I\/II study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy. Blood 130, 4121 (2017).","journal-title":"Blood"},{"key":"297_CR160","unstructured":"Adusumilli P. S. et al. A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy - a preliminary report. Presented at the American Society of Gene and Cell 21st Annual Meeting (2018)."},{"key":"297_CR161","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130\u20133144 (2016).","journal-title":"J. Clin. Invest."},{"key":"297_CR162","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","volume":"51","author":"ME Prosser","year":"2012","unstructured":"Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J. & Jensen, M. C. Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol. Immunol. 51, 263\u2013272 (2012).","journal-title":"Mol. Immunol."},{"key":"297_CR163","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.4049\/jimmunol.1203085","volume":"191","author":"C Ankri","year":"2013","unstructured":"Ankri, C., Shamalov, K., Horovitz-Fried, M., Mauer, S. & Cohen, C. J. Human T cells engineered to express a programmed death 1\/28 costimulatory retargeting molecule display enhanced antitumor activity. J. Immunol. 191, 4121\u20134129 (2013).","journal-title":"J. Immunol."},{"key":"297_CR164","first-page":"djv146","volume":"107","author":"S Kobold","year":"2015","unstructured":"Kobold, S. et al. Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J. Natl Cancer Inst. 107, djv146 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"297_CR165","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 76, 1578\u20131590 (2016).","journal-title":"Cancer Res."},{"key":"297_CR166","doi-asserted-by":"publisher","first-page":"34341","DOI":"10.18632\/oncotarget.9114","volume":"7","author":"ER Suarez","year":"2016","unstructured":"Suarez, E. R. et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget 7, 34341\u201334355 (2016).","journal-title":"Oncotarget"},{"key":"297_CR167","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847\u2013856 (2018).","journal-title":"Nat. Biotechnol."},{"key":"297_CR168","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","volume":"23","author":"S Li","year":"2017","unstructured":"Li, S. et al. Enhanced cancer immunotherapy by chimeric antigen receptor\u2013modified T cells engineered to secrete checkpoint inhibitors. Clin. Cancer Res. 23, 6982\u20136992 (2017).","journal-title":"Clin. Cancer Res."},{"key":"297_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp, L. J. et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 7, 737 (2017).","journal-title":"Sci. Rep."},{"key":"297_CR170","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon, S. & Labarriere, N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology 7, e1364828 (2017).","journal-title":"Oncoimmunology"},{"key":"297_CR171","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s40425-019-0685-y","volume":"7","author":"J Wei","year":"2019","unstructured":"Wei, J. et al. PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J. Immunother. Cancer 7, 209 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"297_CR172","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130518","volume":"10","author":"M Condomines","year":"2015","unstructured":"Condomines, M. et al. Tumor-targeted human T cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition. PLOS ONE 10, e0130518 (2015).","journal-title":"PLOS ONE"},{"key":"297_CR173","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/2326-6066.CIR-15-0263","volume":"4","author":"K Newick","year":"2016","unstructured":"Newick, K. et al. Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. Cancer Immunol. Res. 4, 541\u2013551 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR174","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis, P. A. et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Invest. 127, 929\u2013941 (2017).","journal-title":"J. Clin. Invest."},{"key":"297_CR175","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","volume":"6","author":"N Siriwon","year":"2018","unstructured":"Siriwon, N. et al. CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol. Res. 6, 812\u2013824 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR176","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"297_CR177","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed, S. et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol. Ther. 25, 249\u2013258 (2017).","journal-title":"Mol. Ther."},{"key":"297_CR178","doi-asserted-by":"publisher","first-page":"25538","DOI":"10.1074\/jbc.M110.127951","volume":"285","author":"S Wilkie","year":"2010","unstructured":"Wilkie, S. et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285, 25538\u201325544 (2010).","journal-title":"J. Biol. Chem."},{"key":"297_CR179","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1172\/JCI121491","volume":"129","author":"TN Yamamoto","year":"2019","unstructured":"Yamamoto, T. N. et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J. Clin. Invest. 129, 1551\u20131565 (2019).","journal-title":"J. Clin. Invest."},{"key":"297_CR180","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3389\/fonc.2019.00322","volume":"9","author":"X Xu","year":"2019","unstructured":"Xu, X., Gnanaprakasam, J. N. R., Sherman, J. & Wang, R. A metabolism toolbox for CAR T therapy. Front. Oncol. 9, 322 (2019).","journal-title":"Front. Oncol."},{"key":"297_CR181","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","volume":"167","author":"R Geiger","year":"2016","unstructured":"Geiger, R. et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829\u2013842.e13 (2016).","journal-title":"Cell"},{"key":"297_CR182","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0135","volume":"363","author":"SK Vodnala","year":"2019","unstructured":"Vodnala, S. K. et al. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science 363, eaau0135 (2019).","journal-title":"Science"},{"key":"297_CR183","doi-asserted-by":"publisher","first-page":"8382","DOI":"10.4049\/jimmunol.181.12.8382","volume":"181","author":"T Ando","year":"2008","unstructured":"Ando, T. et al. Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J. Immunol. 181, 8382\u20138390 (2008).","journal-title":"J. Immunol."},{"key":"297_CR184","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski, M., Hombach, A. A. & Abken, H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 257, 83\u201390 (2014).","journal-title":"Immunol. Rev."},{"key":"297_CR185","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133\u20134141 (2012).","journal-title":"Blood"},{"key":"297_CR186","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4, e994446 (2015).","journal-title":"Oncoimmunology"},{"key":"297_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10940-8","volume":"7","author":"OO Yeku","year":"2017","unstructured":"Yeku, O. O., Purdon, T. J., Koneru, M., Spriggs, D. & Brentjens, R. J. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 7, 10541 (2017).","journal-title":"Sci. Rep."},{"key":"297_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru, M., O\u2019Cearbhaill, R., Pendharkar, S., Spriggs, D. R. & Brentjens, R. J. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. J. Transl. Med. 13, 102 (2015).","journal-title":"J. Transl. Med."},{"key":"297_CR189","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697\u20135706 (2011).","journal-title":"Cancer Res."},{"key":"297_CR190","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","volume":"18","author":"D Chinnasamy","year":"2012","unstructured":"Chinnasamy, D. et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672\u20131683 (2012).","journal-title":"Clin. Cancer Res."},{"key":"297_CR191","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-\u03b3 production. Blood 90, 2541\u20132548 (1997).","journal-title":"Blood"},{"key":"297_CR192","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278\u20132288 (2015).","journal-title":"Clin. Cancer Res."},{"key":"297_CR193","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1006\/mthe.2000.0050","volume":"1","author":"H Mizuguchi","year":"2000","unstructured":"Mizuguchi, H., Xu, Z., Ishii-Watabe, A., Uchida, E. & Hayakawa, T. IRES-dependent second gene expression is significantly lower than Cap-dependent first gene expression in a bicistronic vector. Mol. Ther. 1, 376\u2013382 (2000).","journal-title":"Mol. Ther."},{"key":"297_CR194","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/mt.2010.313","volume":"19","author":"L Zhang","year":"2011","unstructured":"Zhang, L. et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol. Ther. 19, 751\u2013759 (2011).","journal-title":"Mol. Ther."},{"key":"297_CR195","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"V Hoyos","year":"2010","unstructured":"Hoyos, V. et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety. Leukemia 24, 1160\u20131170 (2010).","journal-title":"Leukemia"},{"key":"297_CR196","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute, G. et al. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol. Res. 5, 571\u2013581 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"297_CR197","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1158\/1078-0432.CCR-18-1811","volume":"25","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin. Cancer Res. 25, 2915\u20132924 (2019).","journal-title":"Clin. Cancer Res."},{"key":"297_CR198","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl Acad. Sci. USA 113, E7788\u2013E7797 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"297_CR199","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/1566523218666181116093857","volume":"19","author":"S Nair","year":"2019","unstructured":"Nair, S. et al. Functional improvement of chimeric antigen receptor through intrinsic interleukin-15R\u03b1 signaling. Curr. Gene Ther. 19, 40\u201353 (2019).","journal-title":"Curr. Gene Ther."},{"key":"297_CR200","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1182\/blood-2006-06-029173","volume":"109","author":"C Hsu","year":"2007","unstructured":"Hsu, C. et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 109, 5168\u20135177 (2007).","journal-title":"Blood"},{"key":"297_CR201","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1084\/jem.193.2.219","volume":"193","author":"TA Fehniger","year":"2001","unstructured":"Fehniger, T. A. et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193, 219\u2013231 (2001).","journal-title":"J. Exp. Med."},{"key":"297_CR202","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","volume":"33","author":"KC Conlon","year":"2015","unstructured":"Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74\u201382 (2015).","journal-title":"J. Clin. Oncol."},{"key":"297_CR203","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nbt.4181","volume":"36","author":"L Tang","year":"2018","unstructured":"Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707 (2018).","journal-title":"Nat. Biotechnol."},{"key":"297_CR204","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003289","volume":"3","author":"RG Carroll","year":"2008","unstructured":"Carroll, R. G. et al. Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. PLOS ONE 3, e3289 (2008).","journal-title":"PLOS ONE"},{"key":"297_CR205","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23, 2130\u20132141 (2018).","journal-title":"Cell Rep."},{"key":"297_CR206","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. CAR T cells releasing IL-18 convert to T-Bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"297_CR207","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"key":"297_CR208","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-06-0121","volume":"12","author":"MJ Robertson","year":"2006","unstructured":"Robertson, M. J. et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. 12, 4265\u20134273 (2006).","journal-title":"Clin. Cancer Res."},{"key":"297_CR209","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1007\/s00018-013-1425-y","volume":"70","author":"SK Sedimbi","year":"2013","unstructured":"Sedimbi, S. K., Hagglof, T. & Karlsson, M. C. IL-18 in inflammatory and autoimmune disease. Cell. Mol. Life Sci. 70, 4795\u20134808 (2013).","journal-title":"Cell. Mol. Life Sci."},{"key":"297_CR210","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10555-006-9013-3","volume":"25","author":"F Vidal-Vanaclocha","year":"2006","unstructured":"Vidal-Vanaclocha, F. et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev. 25, 417\u2013434 (2006).","journal-title":"Cancer Metastasis Rev."},{"key":"297_CR211","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346\u2013351 (2018).","journal-title":"Nat. Biotechnol."},{"key":"297_CR212","first-page":"204.223","volume":"198","author":"Y Chen","year":"2017","unstructured":"Chen, Y. & Lu, B. Guided delivery of the \u201calarming\u201d cytokine IL-33 to tumor by chimeric antigen receptor T cells. J. Immunol. 198, 204.223 (2017).","journal-title":"J. Immunol."},{"key":"297_CR213","first-page":"432","volume":"27","author":"Li","year":"2019","unstructured":"Li, X. D., A., Lopez, A., Purdon, T. & Brentjens, R. Augmenting CAR T cell mediated antitumor efficacy through genetic modification to secrete a novel cytokine IL-36\u03b3. Mol. Ther. 27, 432\u2013433 (2019).","journal-title":"Mol. Ther."},{"key":"297_CR214","first-page":"320ra323","volume":"8","author":"N Singh","year":"2016","unstructured":"Singh, N., Perazzelli, J., Grupp, S. A. & Barrett, D. M. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci. Transl. Med. 8, 320ra323 (2016).","journal-title":"Sci. Transl. Med."},{"key":"297_CR215","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das, R. K., Vernau, L., Grupp, S. A. & Barrett, D. M. Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 9, 492\u2013499 (2019).","journal-title":"Cancer Discov."},{"key":"297_CR216","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/trf.15287","volume":"59","author":"N Elavia","year":"2019","unstructured":"Elavia, N. et al. Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics. Transfusion 59, 1755\u20131764 (2019).","journal-title":"Transfusion"},{"key":"297_CR217","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","volume":"45","author":"A Schietinger","year":"2016","unstructured":"Schietinger, A. et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45, 389\u2013401 (2016).","journal-title":"Immunity"},{"key":"297_CR218","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1182\/blood.V74.2.786.786","volume":"74","author":"T Totterman","year":"1989","unstructured":"Totterman, T., Carlsson, M., Simonsson, B., Bengtsson, M. & Nilsson, K. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 74, 786\u2013792 (1989).","journal-title":"Blood"},{"key":"297_CR219","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"297_CR220","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nature22367","volume":"545","author":"M Philip","year":"2017","unstructured":"Philip, M. et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545, 452 (2017).","journal-title":"Nature"},{"key":"297_CR221","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer, J. N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129\u20134139 (2013).","journal-title":"Blood"},{"key":"297_CR222","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei, P. et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 126, 3363\u20133376 (2016).","journal-title":"J. Clin. Invest."},{"key":"297_CR223","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112\u20131121 (2016).","journal-title":"J. Clin. Oncol."},{"key":"297_CR224","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nm.4258","volume":"23","author":"A Ghosh","year":"2017","unstructured":"Ghosh, A. et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat. Med. 23, 242 (2017).","journal-title":"Nat. Med."},{"key":"297_CR225","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CRY Cruz","year":"2013","unstructured":"Cruz, C. R. Y. et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122, 2965\u20132973 (2013).","journal-title":"Blood"},{"key":"297_CR226","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.3390\/ijms20112839","volume":"20","author":"R Rotolo","year":"2019","unstructured":"Rotolo, R. et al. CAR-based strategies beyond T lymphocytes: integrative opportunities for cancer adoptive immunotherapy. Int. J. Mol. Sci. 20, 2839 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"297_CR227","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","volume":"10","author":"W Hu","year":"2019","unstructured":"Hu, W., Wang, G., Huang, D., Sui, M. & Xu, Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front. Immunol. 10, 1205 (2019).","journal-title":"Front. Immunol."},{"key":"297_CR228","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/mt.2015.197","volume":"24","author":"MJ Osborn","year":"2016","unstructured":"Osborn, M. J. et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas9, and megaTAL nucleases. Mol. Ther. 24, 570\u2013581 (2016).","journal-title":"Mol. Ther."},{"key":"297_CR229","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai, H. et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119, 5697\u20135705 (2012).","journal-title":"Blood"},{"key":"297_CR230","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai, H. et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122, 1341\u20131349 (2013).","journal-title":"Blood"},{"key":"297_CR231","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."},{"key":"297_CR232","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot, L. et al. Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies. Cancer Res. 75, 3853\u20133864 (2015).","journal-title":"Cancer Res."},{"key":"297_CR233","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017).","journal-title":"Sci. Transl. Med."},{"key":"297_CR234","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ymthe.2018.02.025","volume":"26","author":"C Georgiadis","year":"2018","unstructured":"Georgiadis, C. et al. Long terminal repeat CRISPR-CAR-coupled \u201cuniversal\u201d T cells mediate potent anti-leukemic effects. Mol. Ther. 26, 1215\u20131227 (2018).","journal-title":"Mol. Ther."},{"key":"297_CR235","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","volume":"27","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 27, 154\u2013157 (2017).","journal-title":"Cell Res."},{"key":"297_CR236","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.18632\/oncotarget.15218","volume":"8","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget 8, 17002\u201317011 (2017).","journal-title":"Oncotarget"},{"key":"297_CR237","unstructured":"Barnett, B. Manufacture of allogeneic \u201cUniversal Donor\u201d CAR-T therapies using piggyBac\u2122 and Cas-CLOVER in CAR-TCR Summit, Boston MA https:\/\/poseida.com\/wp-content\/uploads\/2018-CAR-TCR-Summit.P-BCMA-ALLO1-1.pdf (2018)."},{"key":"297_CR238","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113 (2017).","journal-title":"Nature"},{"key":"297_CR239","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","volume":"25","author":"DT MacLeod","year":"2017","unstructured":"MacLeod, D. T. et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol. Ther. 25, 949\u2013961 (2017).","journal-title":"Mol. Ther."},{"key":"297_CR240","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1182\/bloodadvances.2017012823","volume":"2","author":"T Kamiya","year":"2018","unstructured":"Kamiya, T., Wong, D., Png, Y. T. & Campana, D. A novel method to generate T-cell receptor\u2013deficient chimeric antigen receptor T cells. Blood Adv. 2, 517\u2013528 (2018).","journal-title":"Blood Adv."},{"key":"297_CR241","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/cells7100155","volume":"7","author":"C Graham","year":"2018","unstructured":"Graham, C., Jozwik, A., Pepper, A. & Benjamin, R. Allogeneic CAR-T cells: more than ease of access? Cells 7, 155 (2018).","journal-title":"Cells"},{"key":"297_CR242","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/cas.13892","volume":"110","author":"S Iriguchi","year":"2019","unstructured":"Iriguchi, S. & Kaneko, S. Toward the development of true \"off-the-shelf\" synthetic T-cell immunotherapy. Cancer Sci. 110, 16\u201322 (2019).","journal-title":"Cancer Sci."},{"key":"297_CR243","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt1395","volume":"26","author":"JL Zakrzewski","year":"2008","unstructured":"Zakrzewski, J. L. et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat. Biotechnol. 26, 453 (2008).","journal-title":"Nat. Biotechnol."},{"key":"297_CR244","first-page":"157","volume":"119","author":"EP Papapetrou","year":"2009","unstructured":"Papapetrou, E. P., Kovalovsky, D., Beloeil, L., Sant\u2019angelo, D. & Sadelain, M. Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. J. Clin. Invest. 119, 157\u2013168 (2009).","journal-title":"J. Clin. Invest."},{"key":"297_CR245","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli, M. et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31, 928 (2013).","journal-title":"Nat. Biotechnol."},{"key":"297_CR246","first-page":"163","volume":"130 (Suppl. 1)","author":"S van der Stegen","year":"2017","unstructured":"van der Stegen, S. et al. Generation of clonal antigen specific CD8\u03b1\u03b2+ cytotoxic T lymphocytes from renewable pluripotent stem cells for off-the-shelf T cell therapeutics. Blood 130 (Suppl. 1), 163 (2017).","journal-title":"Blood"},{"key":"297_CR247","doi-asserted-by":"crossref","first-page":"LB-108","DOI":"10.1158\/1538-7445.AM2018-LB-108","volume":"78","author":"RL Clarke","year":"2018","unstructured":"Clarke, R. L. et al. Abstract LB-108: Generation of off-the-shelf TCR-less CAR-targeted cytotoxic T cells from renewable pluripotent cells for cancer immunotherapy. Cancer Res. 78, LB-108 (2018).","journal-title":"Cancer Res."},{"key":"297_CR248","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"297_CR249","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"297_CR250","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/leu.2016.180","volume":"31","author":"R Monjezi","year":"2017","unstructured":"Monjezi, R. et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia 31, 186\u2013194 (2017).","journal-title":"Leukemia"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0297-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0297-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0297-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:48:00Z","timestamp":1733939280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0297-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":250,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1038\/s41571-019-0297-y","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"24 October 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.J.B. receives royalties and grant support from JUNO Therapeutics and is a consultant for JUNO Therapeutics\/Celgene. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}